Piper Jaffray analyst Joshua Schimmer says Afrezza sales reported by Sanofi (SNY) have been "lackluster to say the least" while IMS scripts "still don't show signs of life." Pending an inflection point in the coming months for the inhaled insulin, there is a "danger" that Sanofi returns the product to MannKind, Schimmer tells investors in a research note. Such a move could force a full divestiture by MannKind to avoid insolvency, the analyst warns. Schimmer reiterates a Neutral rating on MannKind with a $3.50 price target. The stock closed yesterday up 4c to $4.19.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here